Mumbai Presentation To Netherlands Foreign Investment Agency 28 05 2019
Mumbai Presentation To Netherlands Foreign Investment Agency 28 05 2019
Mumbai Presentation To Netherlands Foreign Investment Agency 28 05 2019
On
Pharmaceutical Sector in India
by
Sudarshan Jain
Secretary General
Indian Pharmaceutical Alliance
Mumbai
30 May 2019 1
Indian Pharmaceutical Alliance
Outline of Presentation
2
IPA: 5/19
Indian Pharmaceutical Industry
IPA: 5/19
Courtesy: McKinsey & Co. 3
Indian Pharmaceutical Industry
Contribution to WHO PQ
APIs
FPPs
Dedicated McKinsey Team working with IPA QF for the last 2.5 years
SOURCE: IPA QF sub-groups 7
IPA: 11/18 Courtesy: McKinsey & Co.
The Industry has continued to show progress- Inspection outcomes in India
have improved and are now more in line with global outcomes
Towards Excellence in Quality 2/4
Global India
2014 2015 2016 2017 2018 2014 2015 2016 2017 2018
Indian inspections
6% 11% 9% 9% 14%
as a share of global
FDA inspection data for CDER and Drug Quality Assurance projects, for
1 Data from Jan – Dec cycle
Jan – Dec cycle (February 25, 2019)
SOURCE: FDA inspection data for CDER (Drug Quality Assurance), data pull on Feb 25, 2019
8
IPA: 5/19
Indian Pharmaceutical Industry
33%
9
IPA: 5/19
Opportunities: European Market is Growing at Healthy Rate
46
43
34
30
4 6 7 5
2 5
0 2
GMP Certificates GMP GMP Certificates GMP GMP Certificates GMP GMP Certificates GMP
2014 Non-Compliance 2015 Non-Compliance 2016 Non-Compliance 2017 Non-Compliance
Statements 2014 Statements 2015 Statements 2016 Statements 2017
8
Business Landscape
10
Indian Pharma industry: Going forward
15
IPA: 11/18
Indian Pharmaceutical Alliance
Current Members (23)
Abbott IPCA
Ajanta J B Chemicals
Alembic Lupin
Alkem Micro
Mankind
Cadila Healthcare
Natco
Cadila Pharmaceuticals
Panacea Biotech
Cipla
Sun
Dr Reddy’s
Torrent
Emcure
Unichem
Glenmark
USV
INTAS Wockhardt 16
IPA: 05/19
Indian Pharmaceutical Alliance
Contribution
• Of domestic sales
57%